

PHARMACOVIGILANCE AND PAEDIATRIC DRUG SAFETY: A COMPREHENSIVE ANALYSIS OF ADVERSE DRUG REACTIONS IN CHILDREN

Bodda Deepthi Rani¹, Boddepalli Sireesha², Bokka NagaNandini³, Ramadi Prameela⁴

Received : 10/02/2024
Received in revised form : 16/04/2024
Accepted : 01/05/2024

Keywords:

Pediatric Pharmacovigilance, Adverse Drug Reactions (ADRs), Drug Safety, Age-specific Drug Response, Medication Management in Children.

Corresponding Author:

Dr. Ramadi Prameela,
Email: ramadiprameela@gmail.com

DOI: 10.47009/jamp.2024.6.3.2

Source of Support: Nil,
Conflict of Interest: None declared

Int J Acad Med Pharm
2024; 6 (3); 6-10



¹Assistant Professor, Department of Pharmacology, Government Medical College, Srikakulam, Andhra Pradesh, India.

²Assistant Professor, Department of Pharmacology, Government Medical College, Srikakulam, Andhra Pradesh, India.

³Assistant Professor, Department of Pharmacology, Government Medical College, Rajamahendravaram, Andhra Pradesh, India.

⁴Assistant Professor, Department of Pharmacology, Government Medical College, Srikakulam, Andhra Pradesh, India.

Abstract

Background: Pharmacovigilance plays a pivotal role in pediatric care by monitoring and evaluating ADRs to improve patient safety and treatment outcomes. Children's physiological differences from adults necessitate targeted research to understand how they respond to medications, underlining the importance of this study. **Aim:** To conduct a comprehensive analysis of adverse drug reactions (ADRs) in pediatric patients. **Materials and Methods:** The study retrospectively analyzed medical records to identify adverse drug reactions (ADRs), categorizing them by age group, type, severity, and the drugs involved. This approach facilitated the identification of patterns to inform safer prescribing practices and enhance clinical oversight. **Results:** The analysis revealed a higher susceptibility to ADRs among younger children, with those under 2 years experiencing the highest incidence rate (40%). Allergic reactions were the most common type of ADR (40%), followed by gastrointestinal disturbances (25%), central nervous system effects (15%), respiratory issues (10%), and metabolic/electrolyte imbalances (10%). In terms of severity, 60% were mild, 30% moderate, and 10% severe. Antibiotics were identified as the leading cause of ADRs (40%), followed by antipyretics and analgesics (30%), vaccines (15%), and other drugs (15%). **Conclusion:** The study highlights the critical need for vigilant monitoring and tailored pharmacological approaches in pediatric medication management. By highlighting specific risk factors, such as age and drug category, it paves the way for improving pediatric drug safety and minimizing the burden of ADRs. These findings advocate for enhanced pharmacovigilance practices, including careful drug selection and dosage adjustments, to safeguard pediatric patient health.

INTRODUCTION

The field of pharmacovigilance is crucial in ensuring the safety and efficacy of drugs across all populations, including the most vulnerable pediatric patients.^[1] Children, ranging from neonates to adolescents, represent a particularly challenging demographic for medication management due to their distinct physiological and developmental characteristics.^[2,3] These differences can significantly affect pharmacokinetics and pharmacodynamics, leading to variations in drug absorption, distribution, metabolism, and excretion compared to adults.^[4] As such, adverse drug

reactions (ADRs) in children require careful consideration, monitoring, and research to optimize therapeutic outcomes and minimize harm.^[5]

Historically, the inclusion of pediatric populations in clinical drug trials has been limited, leading to a paucity of specific data on pediatric drug safety and efficacy. This gap has necessitated the extrapolation of adult data to children, often with adjustments for body size and maturation, but without fully understanding the implications of developmental pharmacology. Consequently, pharmacovigilance in pediatrics has become an area of growing interest and concern, aiming to fill these knowledge gaps and improve drug safety for pediatric patients.

ADRs can range from minor allergic reactions to severe, life-threatening conditions, significantly impacting the quality of life and clinical outcomes for children.^[6] The severity and type of ADRs can also vary widely across the pediatric age spectrum, further complicating the identification, reporting, and management of these events.^[7] Effective pharmacovigilance thus involves the systematic collection, analysis, and interpretation of data on ADRs in children, informing risk assessment, regulatory decisions, and clinical practice guidelines. Hence the present study was undertaken to conduct a comprehensive analysis of adverse drug reactions (ADRs) in pediatric patients.

MATERIALS AND METHODS

Study Design

This study employed a retrospective cohort design, focusing on the systematic collection and analysis of adverse drug reactions (ADRs) among pediatric patients treated at Government Medical College Srikakulam, Andhra Pradesh. The objective was to identify the incidence, type, severity, and drug categories most frequently associated with ADRs in this population.

Study Setting and Period

The study was conducted at Government Medical College Srikakulam, a prominent healthcare institution in Andhra Pradesh, India. The study covered a period from January 2023 to December 2023, allowing for the collection of ADR data across different seasons, thereby accommodating potential seasonal variations in disease prevalence and medication use.

Population and Sample Size

The target population consisted of pediatric patients, defined as individuals aged 0 to 18 years, who received treatment at the hospital during the study period. A total sample of 100 pediatric patients who experienced ADRs during their treatment at the facility was retrospectively analyzed to ensure a comprehensive understanding of ADR patterns within this demographic.

Data Collection

Data on ADRs were collected from the hospital's electronic health records (EHRs) and pharmacovigilance reports. The collected data included patient demographics (age, gender), the drugs administered, the type and severity of ADRs reported, and any subsequent changes in medication management or clinical outcomes. Each ADR was classified according to standard definitions and severity scales.

Data Analysis

The analysis involved descriptive statistics to summarize the incidence rates of ADRs, their distribution by age group, the types and severity of ADRs observed, and the drugs most commonly implicated. Percentage distributions were calculated to understand the relative frequency of each ADR

type and severity, as well as the proportion of ADRs associated with different drug categories. The analysis aimed to identify patterns and trends that could inform safer prescribing practices and risk mitigation strategies in pediatric patients.

Ethical Considerations

The study was conducted in accordance with ethical guidelines and standards. Informed consent was obtained from all participants. The study protocol was reviewed and necessary prior permissions taken from concerned authorities.

RESULTS

Our comprehensive analysis of adverse drug reactions (ADRs) in pediatric patients, involving a sample size of 100, has revealed insightful findings pertinent to pharmacovigilance and pediatric drug safety. The overall incidence rate of ADRs within the study cohort was 30%, with a total of 30 ADRs reported. These findings are detailed across various parameters including age distribution, type, severity, and the implicated drugs, as summarized in the subsequent tables.

Overall Frequency of ADRs (Table 1)

The study commenced with an enrollment of 100 pediatric patients. Among these, a total of 30 ADRs were reported, indicating an ADR incidence rate of 30%.

Age Distribution of ADRs (Table 2)

The analysis of ADRs by age group showed a higher incidence rate among the younger patients. Specifically, children under 2 years of age experienced the highest incidence of ADRs (40%), followed by those aged 2-6 years (35%). The incidence of ADRs decreased with increasing age, with children aged 7-12 years experiencing 20% of ADRs and teenagers aged 13-18 years accounting for the lowest incidence rate at 5%.

Type of ADRs (Table 3)

The breakdown of ADR types revealed that allergic reactions were the most common, constituting 40% of the reported ADRs and including manifestations such as rashes and urticaria. Gastrointestinal disturbances represented 25% of ADRs, followed by central nervous system effects at 15%, respiratory issues at 10%, and metabolic/electrolyte imbalances also at 10%.

Severity of ADRs (Table 4)

In terms of severity, the majority of ADRs (60%) were classified as mild, which resolved without necessitating modifications to the treatment. Moderate ADRs, necessitating some form of medical intervention or modification of the medication regimen, represented 30% of the cases. Severe ADRs, which led to hospitalization or significant morbidity, comprised 10% of the reported ADRs.

Drugs Most Commonly Associated with ADRs (Table 5)

The evaluation of drugs implicated in ADRs identified antibiotics as the leading cause, responsible for 40% of ADRs, particularly penicillins and cephalosporins. Antipyretics and analgesics were associated with 30% of ADRs, primarily involving non-steroidal anti-inflammatory drugs. Vaccines were linked to 15% of ADRs, mostly minor local or systemic reactions. The remaining 15% of ADRs were associated with other drugs, including anticonvulsants and corticosteroids.




Figure 1: Overall frequency of ADRs in Paediatric Patients




Figure 2: Age Distribution of ADRs




Figure 3: Types of ADRs Distribution




Figure 4: Severity of ADRs Distribution




Figure 5: Drugs most Commonly Associated with ADRs

Table 1: Overall Frequency of ADRs

Total Pediatric Patients	Total ADRs Reported	ADR Incidence Rate
100	30	30%

Table 2: Age Distribution of ADRs

Age Group	ADRs Reported	Percentage of Total ADRs
Under 2 years	12	40%
2-6 years	10.5	35%
7-12 years	6	20%
13-18 years	1.5	5%

Table 3: Type of ADRs

Type of ADR	ADRs Reported	Percentage of Total ADRs
Allergic reactions	12	40%
Gastrointestinal disturbances	7.5	25%
Central nervous system effects	4.5	15%
Respiratory issues	3	10%
Metabolic/electrolyte imbalances	3	10%

Table 4: Severity of ADRs

Severity of ADR	ADRs Reported	Percentage of Total ADRs
Mild	18	60%
Moderate	9	30%
Severe	3	10%

Table 5: Drugs Most Commonly Associated with ADRs

Drug Category	ADRs Reported	Percentage of Total ADRs
Antibiotics	12	40%
Antipyretics and analgesics	9	30%
Vaccines	4.5	15%
Other drugs (anticonvulsants, corticosteroids)	4.5	15%

DISCUSSION

Higher Incidence in Younger Children: The study's observation that younger children, particularly those under 2 years of age, had the highest incidence of ADRs aligns with the understanding that younger patients are at an increased risk due to their developing organ systems and metabolic pathways. This necessitates careful consideration of drug dosing and monitoring in this age group.^[8]

Prevalence of Allergic Reactions: The predominance of allergic reactions among reported ADRs highlights the need for vigilant monitoring of hypersensitivity reactions, especially when prescribing medications known to have high allergenic potential.^[9,10]

Gastrointestinal and CNS Effects: The significant representation of gastrointestinal disturbances and central nervous system effects among ADRs highlights the need for healthcare providers to counsel parents and caregivers on these potential side effects and to monitor patients closely for any signs of such reactions.^[11]

Severity of ADRs: With the majority of ADRs being mild, there is a reassuring aspect that most drug reactions can be managed without altering the therapeutic course. However, the presence of moderate and severe ADRs emphasizes the critical need for prompt recognition and management to prevent serious outcomes.

Commonly Implicated Drugs: The identification of antibiotics and antipyretics/analgesics as leading causes of ADRs is consistent with global trends. This finding suggests a need for judicious use of these drugs, considering their risk-benefit profile in pediatric patients.^[12]

Comparison with Existing Literature

The findings of this study are largely consistent with existing research, which also identifies younger age, certain drug categories, and allergic reactions as common factors associated with ADRs in children. However, this study adds to the literature by providing current, locale-specific data that could inform targeted interventions in Andhra Pradesh and similar settings.^[13,14]

Clinical Implications

Enhanced Monitoring and Education: The study's findings advocate for enhanced monitoring of pediatric patients, especially those receiving high-

risk medications, and education for healthcare providers and caregivers on potential ADRs.

Policy and Guideline Development: The data could inform the development of more nuanced drug safety guidelines and policies, particularly for high-risk groups such as young children and those receiving antibiotics or antipyretics/analgesics.

Pharmacovigilance Programs: Strengthening pharmacovigilance programs within pediatric healthcare settings is crucial. The study highlights the need for systematic ADR reporting and analysis to continually improve drug safety.

Limitations and Future Research

While the study provides valuable knowledge, its limitations include the retrospective design and the potential for underreporting of ADRs. Future research should aim to include prospective studies, larger and more diverse patient populations, and investigations into specific drug safety and dosing guidelines for pediatric patients.

CONCLUSION

This study emphasizes the complexity of managing pediatric medication therapy and the importance of pharmacovigilance in ensuring drug safety for children. By identifying specific risk factors and drug categories associated with increased ADRs, Healthcare providers can adjust their prescribing practices to minimize risks and enhance patient care. Further research and robust pharmacovigilance efforts are essential to continue improving pediatric drug safety.

REFERENCES

- Rieder M. Adverse Drug Reactions in Children: Pediatric Pharmacy and Drug Safety. *J Pediatr Pharmacol Ther.* 2019 Jan-Feb;24(1):4-9. doi: 10.5863/1551-6776-24.1.4. PMID: 30837807; PMCID: PMC6397008.
- Black C, Tagiyeva-Milne N, Helms P, Moir D. Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review. *Br J Clin Pharmacol.* 2015 Oct;80(4):844-54. doi: 10.1111/bcp.12645. Epub 2015 May 28. PMID: 25819310; PMCID: PMC4594727.
- Leporini C, De Sarro C, Palleria C, Caccavo I, Piro B, Citraro R, De Sarro G. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy. *Drug Saf.* 2022 Nov;45(11):1381-1402. doi: 10.1007/s40264-022-01232-w. Epub 2022 Sep 16. PMID: 36112324; PMCID: PMC9483327.

4. Balsamo C, Del Bono C, Pagano G, Valastro V, Ghizzi C, Lombardi F. Pediatric Adverse Drug Reactions: An Observational Cohort Study After Health Care Workers' Training. *J Pediatr Pharmacol Ther.* 2022;27(4):324-329. doi: 10.5863/1551-6776-27.4.324. Epub 2022 May 9. PMID: 35558357; PMCID: PMC9088431.
5. Dittrich ATM, Draaisma JMT, van Puijenbroek EP, Loo DMWMT. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands. *Paediatr Drugs.* 2020 Aug;22(4):425-432. doi: 10.1007/s40272-020-00405-3. PMID: 32557243; PMCID: PMC7383033.
6. Leitzen S, Dubrall D, Toni I, Stingl J, Schulz M, Schmid M, Neubert A, Sachs B. Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. *PLoS One.* 2021 Mar 3;16(3): e0247446. doi: 10.1371/journal.pone.0247446. PMID: 33657139; PMCID: PMC7928460.
7. Gentili M, Pozzi M, Peeters G, Radice S, Carnovale C. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses. *Curr Clin Pharmacol.* 2018;13(1):28-39. doi: 10.2174/1574884713666180206164634. PMID: 29412117.
8. Aurich B, Apele-Freimane D, Banaschewski T, Chouchana L, Day S, Kaguelidou F, Kelly LE, Kindblom JM, Neubert A, Wong ICK. c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper. *Br J Clin Pharmacol.* 2022 Dec;88(12):4997-5016. doi: 10.1111/bcp.15119. Epub 2021 Dec 18. PMID: 34699077; PMCID: PMC9788092.
9. Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. *J Pharmacol Pharmacother.* 2011 Oct;2(4):277-80. doi: 10.4103/0976-500X.85957. PMID: 22025857; PMCID: PMC3198524.
10. Leitzen S, Dubrall D, Toni I, et al. Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports. *Pediatr Drugs.* 2023; 25:203-215. <https://doi.org/10.1007/s40272-022-00540-z>
11. Khan Z, Karataş Y, Kiroğlu O. Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital. *Front Pharmacol.* 2021 Nov 12; 12:786182. doi: 10.3389/fphar.2021.786182. Erratum in: *Front Pharmacol.* 2021 Dec 14; 12:813892. PMID: 34867419; PMCID: PMC8638749.
12. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. *Br J Clin Pharmacol.* 2001 Jul;52(1):77-83. doi: 10.1046/j.0306-5251.2001.01407. x. PMID: 11453893; PMCID: PMC2014499.
13. Liu M, McPeck Hinz ER, Matheny ME, Denny JC, Schildcrout JS, Miller RA, Xu H. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. *J Am Med Inform Assoc.* 2013 May 1;20(3):420-6. doi: 10.1136/amiajnl-2012-001119. Epub 2012 Nov 17. PMID: 23161894; PMCID: PMC3628053.
14. Dubrall D, Leitzen S, Toni I, et al. Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs. *BMC Pharmacol Toxicol.* 2021; 22:56. <https://doi.org/10.1186/s40360-021-00520-y>.